Maze Therapeutics (MAZE) Change in Receivables (2026)

Maze Therapeutics' (MAZE) quarterly Change in Receivables came in at $20.0 million in Q1 2026.

Maze Therapeutics (MAZE) Change in Receivables (2026) Analysis & Trends

Maze Therapeutics has disclosed Change in Receivables across 1 years of filings, most recently posting $20.0 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - 22,529.00
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn -39.80 Mn
9 Abivax 90.15 Bn 90.15 Bn - -4.08 Mn
10 Maze Therapeutics 1.31 Bn 1.31 Bn 18.21 Mn 20.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 20.00 Mn
Mar 31, 2026 20.00 Mn